Sagent镇痛药酮咯酸氨丁三醇注射液在美国上市

Sagent镇痛药酮咯酸氨丁三醇注射液在美国上市

                               
登录/注册后可看大图

  

                               
登录/注册后可看大图

发布日期：2014-09-22  来源：pharmabiz  

9月17日，塞进制药(SGNT)宣布，非固醇类抗炎剂酮咯酸氨丁三醇(ketorolac tromethamine)注射液以三种规格在美国上市。

                               
登录/注册后可看大图

据IMS估计，截止到2014年7月的12个月中，酮咯酸(ketorolac)在美国的的销售额约达3400万美元。如同塞进(SGNT)公司的其他所有组合产品，

酮咯酸(ketorolac)也被赋予了安进公司特有的有助于减少用药错误的的Prevent IV Measures SM包装和标签。

酮咯酸氨丁三醇(ketorolac tromethamine)用于缓解短期(<=5days)的，需要阿片类药物的中重度急性疼痛。通常在术后使用。

Sagent Pharma launches ketorolac tromethamine injection, USP

Schaumburg, Illinois Friday, September 19, 2014, 17:00

Sagent Pharmaceuticals, announced the launch of ketorolac tromethamine injection, USP, a nonsteroidal anti-inflammatory agent, in three preservative-free glass vials. According to IMS, for the 12 months ending July 2014, the US market for ketorolac approximated $34 million. As with all products in Sagent's portfolio, ketorolac features Sagent's PreventIV MeasuresSM packaging and labelling, designed to help reduce medication errors. Ketorolac tromethamine injection, USP is indicated for the short-term (=5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.

没时间发帖都看帖学习了